darunavir (Prezista®)

Reference No. 2579

Publication date:

16/07/2015

Appraisal information

darunavir (Prezista®) 75 mg film-coated tablet
darunavir (Prezista®) 150 mg film-coated tablet
darunavir (Prezista®) 300 mg film-coated tablet
darunavir (Prezista®) 600 mg film-coated tablet
darunavir (Prezista®) 800 mg film-coated tablet
darunavir (Prezista®) 100 mg/ml oral suspension

Company:	Janssen-Cilag Ltd
BNF category:	Infections
NMG meeting date:	13/05/2015
AWMSG meeting date:	17/06/2015

Submission Type:	Limited Submission
Status:	Recommended
Advice No:	1815
Ratification by Welsh Government:	15/07/2015

Current Progress

Submission
received

NMG
meeting

AWMSG
meeting

Ratification by
Welsh Government

AWMSG advice

Darunavir (Prezista®) co-administered with low dose ritonavir in combination with other antiretroviral medicinal products is recommended as an option for use within NHS Wales for the treatment of human immunodeficiency virus (HIV-1) infection in paediatric patients from the age of three years and at least 15 kg body weight.

Final Appraisal Recommendation (FAR)

Download

darunavir (Prezista) 2579 FAR

AWMSG Secretariat Appraisal Report (ASAR)

Download

daruavir (Prezista) 2579 ASAR

darunavir (Prezista) 2246 ASAR

darunavir (Prezista) 403 ASAR

Clinical Expert (CE) Summary

Download

darunavir (Prezista) 2579 CE summary